Today: 7 February 2026
Subscribe
Browse Category

Pharmaceuticals News 10 December 2025 - 14 December 2025

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

GSK Stock News & Forecast (Week Ahead): CHMP Endorsements, FDA Label Expansion, Buyback Updates — Updated Dec. 14, 2025

Updated: Sunday, December 14, 2025 (markets closed; prices reflect the most recent close). GSK plc (LSE: GSK / NYSE: GSK) heads into mid‑December with a rare “cluster catalyst” setup: multiple fresh European regulator panel endorsements, a new U.S. label expansion for an antibiotic, and steady buyback activity. That combination doesn’t guarantee a breakout (stocks are fickle creatures), but it does give investors a clearer map of what could move GSK shares in the days ahead. As of the latest available trading data, GSK’s U.S. ADR last traded around $48.81. In London, the most recent close was 1,824.5p (Dec. 12, 2025).
14 December 2025
··
Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Milestone Pharmaceuticals (MIST) Stock Update: FDA Approves CARDAMYST (Etripamil) — This Week’s Volatility, Analyst Forecasts, and What to Watch Next (Updated Dec. 12, 2025)

Updated: Friday, December 12, 2025 (U.S. market close) Milestone Pharmaceuticals Inc. (NASDAQ: MIST) closed out the week in the spotlight after the company announced U.S. FDA approval of CARDAMYST™ (etripamil)—positioning Milestone to transition from a development-stage biotech to a commercial-stage cardiovascular company. GlobeNewswire+1 The stock action was anything but calm. MIST closed at $2.41 on Dec. 12, down 18.31%, after swinging through a wide intraday range and printing exceptionally heavy volume. After-hours trading showed a modest rebound. StockAnalysis Below is a detailed breakdown of the latest Milestone Pharmaceuticals news, this week’s trading story, forecasts and analyst targets, and the week-ahead
14 December 2025
··
Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck (MRK) Stock Update: This Week’s News, Key Catalysts, and the Week-Ahead Outlook (Updated Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) ended Friday, December 12, 2025, at $100.30, climbing 1.30% on the day and finishing slightly higher for the week after a choppy stretch driven by vaccine-policy headlines and scrutiny around RSV preventive therapies. StockAnalysis Below is a detailed, Google News/Discover–ready look at what moved Merck stock this week, what the latest company and sector headlines mean for MRK, what analysts are forecasting, and what investors are watching in the week ahead. Merck stock performance this week: A late rebound after early pressure Closing price (Dec. 12): $100.30.MRK’s weekly story was less about a single
13 December 2025
··
Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Pfizer Stock (PFE) Outlook: GLP‑1 Weight‑Loss Deal, Tukysa Trial Win, Dividend Declared — and the Big Catalyst Next Week (Updated Dec. 12, 2025)

Updated Friday, Dec. 12, 2025. Pfizer (NYSE: PFE) heads into the final full trading week before the holidays with a familiar mix of catalysts: pipeline updates that support its post‑COVID growth narrative, dealmaking in the red‑hot obesity space, and renewed regulatory headlines around COVID‑19 vaccines. Add in a freshly declared quarterly dividend and an upcoming 2026 guidance call, and Pfizer stock is setting up for another headline-driven stretch. As of Friday’s close, Pfizer shares finished at $25.85 (up about 0.19% on the day), after trading between $25.72 and $26.04, with volume around 23 million shares. What moved Pfizer stock this
13 December 2025
···
Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

Johnson & Johnson Stock (JNJ) Jumps Near 52-Week Highs on FDA Approval and Oncology Data — Week in Review, Week Ahead (Updated Dec. 12, 2025)

(SEO): Johnson & Johnson (NYSE: JNJ) climbed to $211.58 this week as investors weighed FDA approval news, breakthrough oncology data, and fresh talc-trial risk. Reuters+3Investing.com+3JNJ.com+3 Johnson & Johnson stock (NYSE: JNJ) capped a volatile but decisively positive week by closing at $211.58 on Friday, Dec. 12, 2025, extending a sharp rebound that pushed shares to the doorstep of fresh 52‑week highs. Investing.com The move came as investors digested a cluster of market-moving headlines: At the macro level, the Federal Reserve’s quarter-point rate cut earlier in the week added another tailwind for large, defensive healthcare names as investors rotated toward perceived
13 December 2025
··
Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Eli Lilly Stock (LLY) This Week: Retatrutide Breakthrough, EU Mounjaro Expansion and Orforglipron Fast‑Track Talk — Week Ahead Outlook (Updated Dec. 12, 2025)

Updated: December 12, 2025Company: Eli Lilly and Company (NYSE: LLY)Stock price (last close):$1,027.51 MarketWatch Eli Lilly stock closed the week at $1,027.51 after a late-week rally, outperforming a softer broader market session on Friday. MarketWatch The catalyst mix was familiar—but still powerful: blockbuster momentum in obesity/diabetes, fresh late-stage data that raises the bar for next-generation weight loss drugs, and a steady stream of regulatory and access headlines that keep Lilly’s pipeline and pricing strategy in the spotlight. This week’s narrative was dominated by three themes investors will keep debating into the week ahead: (1) how big retatrutide can become—and whether
13 December 2025
···
Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Milestone Pharmaceuticals (MIST) Stock This Week: FDA Approves CARDAMYST, Shares Whipsaw Into the Weekend — Week Ahead Outlook (Updated Dec. 13, 2025)

Updated: December 13, 2025 Milestone Pharmaceuticals Inc. (Nasdaq: MIST) just crossed the line that separates “clinical-stage story stock” from “commercial execution stock.” Late Friday, the company announced FDA approval of CARDAMYST™ (etripamil)—a self-administered nasal spray for adults to convert acute symptomatic episodes of paroxysmal supraventricular tachycardia (PSVT) to sinus rhythm. GlobeNewswire And because markets love drama, MIST didn’t celebrate with a calm, rational repricing. Instead, the stock spent the week building into the decision, then delivered a violent rollercoaster session into Friday’s close—before the after-hours approval news hit. Now investors head into next week with a new reality: the regulatory
13 December 2025
··
Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly stock LLY after hours on Dec. 12, 2025: Mounjaro pediatric EU nod, FDA orforglipron fast-track scrutiny, and what to watch next

Eli Lilly and Company shares ended Friday, Dec. 12, 2025 higher — and held roughly steady in after-hours trading — as investors weighed a fresh European regulatory boost for Mounjaro, new reporting on the FDA’s internal debate over speeding up a decision on Lilly’s oral obesity pill, and late-stage oncology data presented at a major medical meeting. After the bell: LLY finished the regular session at $1,027.51 (+1.80%) and traded in a tight range in the first part of the after-hours session, hovering near $1,028–$1,029. MarketWatch+2StockAnalysis+2 Note on timing: Saturday, Dec. 13, 2025 is a weekend, so U.S. stock markets
12 December 2025
··
Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck (MRK) Stock News Today: Winrevair EU Expansion, Keytruda Patent Headwinds, Analyst Forecasts and What Investors Watch (Dec. 12, 2025)

Merck & Co., Inc. (NYSE: MRK) stock traded higher on Friday, December 12, 2025, as investors weighed a new European regulatory tailwind for pulmonary arterial hypertension drug WINREVAIR (sotatercept) against a backdrop of policy-driven vaccine headlines, Keytruda-related legal friction in Europe, and a steady stream of Wall Street price-target updates. As of 17:07 UTC (midday New York trading), MRK shares were at $99.69, up $0.68 (+0.69%) on the session. Merck stock price: where MRK stands on Dec. 12, 2025 MRK enters the final stretch of 2025 after a solid two-day run earlier in the week. On Thursday, Dec. 11, Merck
12 December 2025
···
Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Milestone Pharmaceuticals (MIST) Stock in Focus on Dec. 12, 2025: FDA Decision Countdown, Latest News, Analyst Forecasts, and Key Risks

Updated: December 12, 2025Company: Milestone Pharmaceuticals Inc. ( NASDAQ: MIST ) Milestone Pharmaceuticals Inc. stock is drawing heightened attention on December 12, 2025 , as investors position ahead of a make-or-break FDA decision for the company’s lead program, CARDAMYST™ (etripamil) nasal spray , aimed at treating paroxysmal supraventricular tachycardia (PSVT) . The regulatory catalyst arrives after a volatile year that included an FDA Complete Response Letter (CRL) earlier in 2025, followed by the FDA’s acceptance of Milestone’s resubmission and a new target action date set for mid-December.GlobeNewswire+ 2GlobeNewswire+ 2 In the market, MIST shares closed at $2.95 on Dec. 11
12 December 2025
·
Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly Stock (NYSE: LLY) in Focus: Retatrutide’s Near-30% Weight-Loss Data, FDA Fast-Track Questions for Orforglipron, and Fresh Analyst Forecasts (Dec. 12, 2025)

Eli Lilly (LLY) stock is moving as investors weigh standout retatrutide Phase 3 results, a Reuters report on FDA review timing for orforglipron, and updated Wall Street price targets. Published: December 12, 2025 Eli Lilly and Company stock (NYSE: LLY) is back in the spotlight on December 12, 2025, as the market digests a rapid sequence of obesity-pipeline headlines—alongside new questions about regulatory process, manufacturing scale-up, and what “priced for perfection” really means for one of healthcare’s most valuable companies. As of the latest quote available Friday, LLY traded around $1,009 per share, modestly higher on the day. Below is
12 December 2025
··
Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly (LLY) Stock After Hours on December 11, 2025: Retatrutide Breakthrough, $6B Plant — and What to Watch Before Friday’s Open

Eli Lilly and Company (NYSE: LLY) ended Thursday’s session back near record territory as Wall Street digested stunning new weight‑loss data from its experimental obesity drug retatrutide, a massive new U.S. manufacturing investment, and fresh signs of global expansion for its GLP‑1 franchise. As of Thursday’s close, Eli Lilly shares were trading around $1,006, up roughly 1–1.5% on the day, after swinging between an intraday high above $1,030 and a low just under $990.Investing.com+1 Late in the session and into after‑hours trading, the stock hovered slightly above the close near $1,009, according to real‑time data. The move leaves LLY only
11 December 2025
···
Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Centessa Pharmaceuticals (CNTA) Stock on December 11, 2025: CEO Shake‑Up, Analyst Upgrades and 2026 Orexin Catalysts

Date: December 11, 2025 Centessa Pharmaceuticals plc (NASDAQ: CNTA) is back in the spotlight after a major leadership announcement and a sharp intraday pullback in its share price. On December 11, 2025, the company unveiled a CEO transition that will take effect at the start of 2026, just as its orexin program heads toward pivotal studies.GlobeNewswire+1 Shares of Centessa traded around the high‑$20s on Thursday afternoon, down meaningfully on the day following the news. Earlier in the session, financial data service GuruFocus flagged an 8.4% drop to roughly $27 per share, underscoring how sensitive the stock remains to shifts in
11 December 2025
··
Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

Telix Pharmaceuticals (TLX) Stock: Varian Deal, ProstACT Milestone and Class Actions Redraw the 2025 Outlook

December 11, 2025 Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX) is ending 2025 in a paradoxical position: commercially successful, rich in late‑stage oncology assets, but trading near its 12‑month lows amid SEC scrutiny, an FDA setback and a growing stack of class‑action lawsuits. At the same time, new clinical milestones and a fresh collaboration with Varian are reinforcing the long‑term radiopharmaceutical growth story. This overview pulls together today’s news, the latest clinical and legal developments, and current analyst forecasts as of 11 December 2025. Telix share price today: depressed after a volatile year By midday in New York on 11
11 December 2025
···
Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

Immunovant (IMVT) Stock Jumps After $550 Million Share Offering as Graves’ Disease Launch Comes Into Focus

NEW YORK – December 11, 2025 – Shares of Immunovant, Inc. (NASDAQ: IMVT) were sharply in focus on Thursday after the clinical‑stage immunology company announced a $550 million common stock financing designed to fund development and a potential commercial launch of its lead FcRn inhibitor, IMVT‑1402, in Graves’ disease.Immunovant, Inc.+1 By late afternoon, Immunovant stock was trading around $25.75, up roughly 9% on the day, with an intraday range between $22.03 and $25.87, giving the company a market value of about $4 billion.Stock Titan That upbeat finish came despite an initial sell‑off; one early report noted shares dropped around 7%
11 December 2025
····
AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Stock (ABBV): HSBC Upgrade, Dividend Hike and New FDA Win Reshape the 2025 Outlook

AbbVie Inc. (NYSE: ABBV) has quietly turned into one of 2025’s standout large‑cap pharma stories. Shares are up roughly a mid‑20% percentage year‑to‑date, outpacing the broader market, powered by booming sales of Skyrizi and Rinvoq, a fresh dividend hike, and a string of oncology milestones — capped by an HSBC upgrade that just put AbbVie on the firm’s “preferred buys” list for 2026. Barchart.com+224/7 Wall St.+2 At the same time, the stock is still trading below its early‑October high, and investors are weighing Humira’s ongoing decline, softness in aesthetics, and regulatory risk against that growth story. Here’s a detailed look
11 December 2025
···
Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

Eli Lilly (LLY) Stock After the $1 Trillion Milestone: Latest News, Analyst Targets and 2026 Outlook

On November 21, 2025, Eli Lilly and Company (NYSE: LLY) became the first pharmaceutical group ever to cross a $1 trillion market value, lifted by surging demand for its obesity and diabetes drugs Mounjaro and Zepbound.Reuters+2Financial Times+2 Since then, investors have been digesting that historic moment alongside a fresh wave of drug data, a multibillion‑dollar manufacturing build‑out in Alabama, and a drumbeat of new analyst forecasts. Here’s a detailed, news‑driven look at where Eli Lilly stock stands today and what the latest information since 11/21/2025 suggests about its 2026 outlook. Eli Lilly (LLY) Stock Snapshot as of December 11, 2025
11 December 2025
·
Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (PFE) Stock Premarket Today, Dec. 11, 2025: Marshall Wace Exit, Obesity Drug Deals and 2026 Guidance in Focus

Pfizer (NYSE: PFE) heads into Thursday’s session with its share price hovering around yesterday’s close, as investors digest a flurry of news on cost cuts, obesity drug deals, and a big hedge fund trimming its stake. As of around 6:05 a.m. ET on Thursday, December 11, real‑time feeds put Pfizer stock near $25.78, roughly flat versus Wednesday’s close of $25.78 after a 1.78% gain in the prior session.StockAnalysis+1 The stock has traded between $20.92 and $27.69 over the past 12 months, and daily volume on Wednesday was around 43–44 million shares, close to its recent average.Investing.com+1 Despite its recent rebound,
11 December 2025
··
Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

Pfizer Stock Today: Obesity Deal, Cancer Breakthroughs and Job Cuts Shape PFE’s 2025 Outlook

As of the session on 10 December 2025, Pfizer Inc. (NYSE: PFE) is trading around $25.5 per share, up modestly on the day and still far below its 2021 peak. The stock now combines a high dividend yield of roughly 6.5–7% with one of the cheapest valuations in big pharma, making it a focal point for income and value investors alike. CoinCentral Today’s move in PFE is being driven by a cluster of fresh catalysts: Below is a detailed, news‑driven look at Pfizer stock today — including the latest news, forecasts and analysis relevant to 10 December 2025. 1. PFE
10 December 2025
··
Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Olema Pharmaceuticals (OLMA) Stock Hits New 52‑Week High on December 10, 2025: What Investors Need to Know

Published: December 10, 2025 Olema Pharmaceuticals Stock Rallies to Fresh Highs Olema Pharmaceuticals, Inc. (NASDAQ: OLMA), which now brands itself as Olema Oncology, is having another breakout session on December 10, 2025. During Wednesday’s trading, OLMA: Over the past 12 months, OLMA’s share price has climbed from below $3 to nearly $30, according to Danelfin and CoinCodex ranges, reflecting a more than tenfold move at the extremes. Danelfin AI+1 Today’s spike is not a random move. It’s being driven by a cluster of catalysts that all hit investors’ screens at once: positive read‑through from a Roche breast cancer drug trial,
10 December 2025
·
1 … 22 23 24 25 26 … 34

Stock Market Today

Lam Research stock price jumps 8% as chip rally returns — what to watch next week

Lam Research stock price jumps 8% as chip rally returns — what to watch next week

7 February 2026
New York, Feb 7, 2026, 15:10 EST — Market closed. Lam Research Corp (LRCX.O) shares jumped 8.3% on Friday to close at $231.01. The stock was little changed after hours at $230.96. (MarketWatch) With U.S. markets shut for the weekend, the open question is whether Friday’s bounce sticks into Monday. Lam sells tools used to make semiconductors, so the stock often trades as a read-through on factory spending tied to AI data centers and memory. Friday’s risk-on swing pushed the Dow above 50,000 for the first time and lifted the PHLX semiconductor index — a barometer for chip stocks —
Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

Goldman Sachs stock jumps on Anthropic AI push — what to watch before Monday

7 February 2026
Goldman Sachs shares jumped 4.3% to $928.75 Friday after confirming it is working with AI startup Anthropic on internal “AI agents.” The stock’s rally helped lift the Dow above 50,000 for the first time. Delayed U.S. jobs and inflation data are due midweek and could affect rate expectations. Goldman also filed for new structured notes tied to the Russell 2000 and S&P 500.
Go toTop